» Articles » PMID: 34439268

MicroRNAs As Potential Predictors of Response to CDK4/6 Inhibitor Treatment

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Aug 27
PMID 34439268
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have emerged as novel treatment options in the management of advanced or metastatic breast cancer. MicroRNAs are endogenous non-coding 19-22-nucleotide-long RNAs that regulate gene expression in development and tumorigenesis. Herein, we systematically review all microRNAs associated with response to CDK4/6 inhibitors in solid tumors and hematological malignancies. Eligible articles were identified by a search of the MEDLINE and ClinicalTrials.gov databases for the period up to1 January 2021; the algorithm consisted of a predefined combination of the words "microRNAs", "cancer" and "CDK 4/6 inhibitors". Overall, 15 studies were retrieved. Six microRNAs (miR-126, miR-326, miR3613-3p, miR-29b-3p, miR-497 and miR-17-92) were associated with sensitivity to CDK4/6 inhibitors. Conversely, six microRNAs (miR-193b, miR-432-5p, miR-200a, miR-223, Let-7a and miR-21) conferred resistance to treatment with CDK4/6 inhibitors. An additional number of microRNAs (miR-124a, miR9, miR200b and miR-106b) were shown to mediate cellular response to CDK4/6 inhibitors without affecting sensitivity to treatment. Collectively, our review provides evidence that microRNAs could serve as predictive biomarkers for treatment with CDK4/6 inhibitors. Moreover, microRNA-targeted therapy could potentially maximize sensitivity to CDK4/6 inhibition.

Citing Articles

Targeting CDK4/6 in breast cancer.

Shanabag A, Armand J, Son E, Yang H Exp Mol Med. 2025; 57(2):312-322.

PMID: 39930131 PMC: 11873051. DOI: 10.1038/s12276-025-01395-3.


Potential Target of CDK6 Signaling Pathway for Cancer Treatment.

Basnet R, Amissah O, Basnet B, Huang R, Sun Y, Habimana J Curr Drug Targets. 2024; 25(11):724-739.

PMID: 39039674 DOI: 10.2174/0113894501313781240627062206.


Liquid biopsy utilizing miRNA in patients with advanced breast cancer treated with cyclin‑dependent kinase 4/6 inhibitors.

Kubeczko M, Tudrej P, Tyszkiewicz T, Krzywon A, Oczko-Wojciechowska M, Jarzab M Oncol Lett. 2024; 27(4):181.

PMID: 38464342 PMC: 10921259. DOI: 10.3892/ol.2024.14314.


Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine Therapy.

Torrisi R, Vaira V, Giordano L, Fernandes B, Saltalamacchia G, Palumbo R Int J Mol Sci. 2024; 25(3).

PMID: 38338777 PMC: 10855102. DOI: 10.3390/ijms25031498.


A narrative review about CDK4/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer.

Zhao S, Zhang H, Yang N, Yang J Transl Cancer Res. 2023; 12(6):1617-1634.

PMID: 37434680 PMC: 10331716. DOI: 10.21037/tcr-22-2807.


References
1.
Kaukoniemi K, Rauhala H, Scaravilli M, Latonen L, Annala M, Vessella R . Epigenetically altered miR-193b targets cyclin D1 in prostate cancer. Cancer Med. 2015; 4(9):1417-25. PMC: 4567026. DOI: 10.1002/cam4.486. View

2.
Xu L, Beckebaum S, Iacob S, Wu G, Kaiser G, Radtke A . MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol. 2013; 60(3):590-8. DOI: 10.1016/j.jhep.2013.10.028. View

3.
Zou D, Wang D, Li R, Tang Y, Yuan L, Long X . MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK. Tumour Biol. 2015; 36(9):6725-32. DOI: 10.1007/s13277-015-3365-7. View

4.
Johnson C, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D . The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 2007; 67(16):7713-22. DOI: 10.1158/0008-5472.CAN-07-1083. View

5.
Romero-Cordoba S, Salido-Guadarrama I, Rodriguez-Dorantes M, Hidalgo-Miranda A . miRNA biogenesis: biological impact in the development of cancer. Cancer Biol Ther. 2014; 15(11):1444-55. PMC: 4622859. DOI: 10.4161/15384047.2014.955442. View